inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Abstract
Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis . The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhA was identified as the target of activated INH by an M. smegmatis missense mutation that conferred co-resistance to both INH and Ethionamide (ETH) (129).”
From Mycobacterium smegmatis: The Vanguard of Mycobacterial Research (2023) · cites this paper as [129]
Citations
Cites
Introduction to Protein Structure
Branden, C. I., & Tooze, J. (2012) · Garland Science eBooks · doi:10.1201/9781136969898 · Cited by 2,382
Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis
Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Lowrie, D., Colston, M. J., & Cole, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)90417-f · Cited by 1,337
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Snapper, S. B., Melton, R. E., Mustafa, S., Kieser, T., & Jr, W. R. J. (1990) · Molecular Microbiology · doi:10.1111/j.1365-2958.1990.tb02040.x · Cited by 1,237
Self-citationThe Emergence of Drug-Resistant Tuberculosis in New York City
Frieden, T. R., Sterling, T., Pablos-Mendez, A., Kilburn, J. O., Cauthen, G. M., & Dooley, S. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302253280801 · Cited by 939
Tuberculosis in developing countries: burden, intervention and cost.
Murray, C. J. L., Styblo, K., & Rouillon, A. (1990) · PubMed · Cited by 571
[25] Genetic systems for mycobacteria
Jacobs, W. R., Kalpana, G. V., Cirillo, J. D., Pascopella, L., Snapper, S. B., Udani, R. A., Jones, W., Barletta, R. G., & Bloom, B. R. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)04027-l · Cited by 433
Self-citationSnider, D. E., & Roper, W. L. (1992) · New England Journal of Medicine · doi:10.1056/nejm199203053261011 · Cited by 382
Combs, D. L., O'Brien, R. J., & Geiter, L. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-76-3-112-6-397 · Cited by 315
Takayama, K., Wang, L., & David, H. L. (1972) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.2.1.29 · Cited by 292
Research works printed but not linked: 8
- BEGGS, W.H., AM REV RESPIR DIS 102: 94 (1969).
- GOPINATHAN, K.P., SPECIFICITY OF ISONIAZID ACTION AGAINST MYCOBACTERIA AND A POSSIBLE MECHANISM FOR THE DEVELOPMENT OF DRUG-RESISTANCE, CURRENT SCIENCE 50: 216 (1981).
- GRUMBACH, F, REVUE DE TUBERCULOSE ET DE PNEUMOLOGIE 25: 1365 (1961).
- MIDDLEBROOK, G, AMERICAN REVIEW OF TUBERCULOSIS 65: 765 (1952).
- MURRAY, C. J. L., BULLETIN OF THE INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE 65: 6 (1990).
- Murray, C., Disease Control Priorities in Developing Countries: 233 (1993).
- OFFE, H.A., ZEITSCHRIFT FUR NATURFORSCHUNG 76: 462 (1952).
- PANSY, F, INVITRO STUDIES ON ISONICOTINIC ACID HYDRAZIDE, AMERICAN REVIEW OF TUBERCULOSIS 65: 761 (1952).
Cited by
Items 201–300 of 1,000
Bhatt, A., Kremer, L., Dai, A. Z., Sacchettini, J. C., & Jacobs, W. R. (2005) · Journal of Bacteriology · doi:10.1128/jb.187.22.7596-7606.2005 · Cited by 126
“Although the structures of mycolic acids have been well characterized, the genetics and enzymology of mycolic acid biosynthesis have only recently begun to be elucidated (1, 2, 15, 20, 32, 36, 37, 42, 47).”
BackgroundInfluentialSelf-citationSaint‐Joanis, B., Souchon, H., Wilming, M., Johnsson, K., Alzari, P. M., & Cole, S. T. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3380753 · Cited by 139
Preclinical evaluation of novel antibacterial agents by microbiological and molecular techniques
O’Neill, A. J., & Chopra, I. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.8.1045 · Cited by 136
“2 Use of resistant mutants to define mode of action In instances where drug-resistant mutants have been recovered, these may be employed to examine the basis of antibacterial action through genetic approaches [100,101].”
BackgroundMycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid
Argyrou, A., Vetting, M. W., Aladegbami, B. G., & Blanchard, J. S. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1089 · Cited by 131
“smegmatis mutants that conferred resistance to isoniazid in vitro”
BackgroundMatteelli, A., Migliori, G. B., Cirillo, D. M., Centis, R., Girardi, E., & Raviglione, M. C. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.5.857 · Cited by 146
New approaches to antimicrobial discovery
Lewis, K. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.002 · Cited by 143
Phetsuksiri, B., Baulard, A. R., Cooper, A. M., Minnikin, D. E., Douglas, J. D., Besra, G. S., & Brennan, P. J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1042 · Cited by 127
“INH is a prodrug which requires activation by the endogenous mycobacterial enzyme catalase-peroxidase (KatG) (20, 52) to form an electrophilic species (13, 46, 47) before reacting with targets such as InhA (1).”
BackgroundInfluentialPuech, V., Guilhot, C., Perez, E., Tropis, M., Armitige, L. Y., Gicquel, B., & Daffé, M. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02953.x · Cited by 121
“†Present address: Institut de Pharmacologie et de Biologie Structurale (UMR 5089), 205, Route de Narbonne, 31077 Toulouse cedex, France. being one of the targets of the antituberculous drug isoniazid (Banerjee et al., 1994; Vilchèze et al., 2000).”
BackgroundKaplan, N., Albert, M., Awrey, D., Bardouniotis, E., Berman, J., Clarke, T., Dorsey, M., Hafkin, B., Ramnauth, J., Romanov, V., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01411-12 · Cited by 114
“aureus provided evidence that FabI is essential in vivo in at least some bacterial species and demonstrated that FabI is amenable to inhibition by small, drug-like compounds (3, 5, 6, 8, 24, 27, 28, 33, 36, 42, 52, 54).”
BackgroundTB drug discovery: addressing issues of persistence and resistance
Smith, C. V., Sharma, V., & Sacchettini, J. C. (2003) · Tuberculosis · doi:10.1016/j.tube.2003.08.019 · Cited by 128
Encinas, L., O’Keefe, H. P., Neu, M., Remuiñán, M. J., Patel, A., Guardia, A. C., Davie, C. P., Pérez-Macías, N., Yang, H., Convery, M. A., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401326j · Cited by 119
Biomimetic Chemical Catalysts in the Oxidative Activation of Drugs
Bernadou, J., & Meunier, B. (2004) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.200303191 · Cited by 121
Dhandayuthapani, S., Zhang, Y., Mudd, M. H., & Deretic, V (1996) · Journal of Bacteriology · doi:10.1128/jb.178.12.3641-3649.1996 · Cited by 120
“However, not all INH strains have mutations in katG (13, 22) or in another locus, inhA, implicated in mycolic acid synthesis and believed to represent a target for INH action (2).”
BackgroundMolecular basis for the exquisite sensitivity of Mycobacterium tuberculosis to isoniazid
Zhang, Y., Dhandayuthapani, S., & Deretic, V. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.23.13212 · Cited by 119
Tsukahara, K., Hata, K., Nakamoto, K., Sagane, K., Watanabe, N., Kuromitsu, J., Kai, J., Tsuchiya, M., Ohba, F., Jigami, Y., et al. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03481.x · Cited by 118
“Mutations in the drug target might reduce the binding of the drug, causing drug resistance (Banerjee et al., 1994).”
BackgroundBasso, L. A., da Silva, L. P., Fett‐Neto, A. G., de Azevedo, W. F., Moreira, Í. D. S., Palma, M. S., Calixto, J. Β., Filho, S. A., dos Santos, R. R., Soares, M. B. P., et al. (2005) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762005000600001 · Cited by 147
“tuberculosis inhA structural gene (InhA or ENR), which is located downstream of an ORF coding for a β-ketoacyl reductase (MabA) in the inhA operon, has been shown to be a major target for isoniazid (Banerjee et al. 1994).”
BackgroundSlayden, R. A., & Barry, C. E. (2002) · Tuberculosis · doi:10.1054/tube.2002.0333 · Cited by 115
Progress in Targeting Cell Envelope Biogenesis in Mycobacterium Tuberculosis
Jackson, M., McNeil, M. R., & Brennan, P. J. (2013) · Future Microbiology · doi:10.2217/fmb.13.52 · Cited by 112
Dover, L. G., Cerdeño-Tárraga, A. M., Pallen, M. J., Parkhill, J., & Besra, G. S. (2004) · FEMS Microbiology Reviews · doi:10.1016/j.femsre.2003.10.001 · Cited by 114
Determination of Selectivity and Efficacy of Fatty Acid Synthesis Inhibitors
Kodali, S., Galgoci, A. M., Young, K., Painter, R. E., Silver, L. L., Herath, K. B., Singh, S. B., Cully, D. F., Barrett, J. F., Schmatz, D. M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406848200 · Cited by 116
Frénois, F., Engohang‐Ndong, J., Locht, C., Baulard, A. R., & Villeret, V. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.020 · Cited by 131
Versatile polyketide enzymatic machinery for the biosynthesis of complex mycobacterial lipids
Gokhale, R. S., Saxena, P., Chopra, T., & Mohanty, D. (2007) · Natural Product Reports · doi:10.1039/b616817p · Cited by 134
Guo, H., Seet, Q., Denkin, S. M., Parsons, L. M., & Zhang, Y. (2006) · Journal of Medical Microbiology · doi:10.1099/jmm.0.46718-0 · Cited by 149
“One of these targets is InhA, an NADHdependent enoyl acyl carrier protein reductase involved in cell wall mycolic acid synthesis (Banerjee et al., 1994).”
InfluentialMiotto, P., Piana, F., Penati, V., Canducci, F., Migliori, G. B., & Cirillo, D. M. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00083-06 · Cited by 124
“Rifampin (RIF) resistance is due to mutation in a relatively small fragment (81 bp) of the rpoB gene encoding for the -subunit of the RNA polymerase (12, 29, 35); isoniazid (INH) resistance is caused by mutations in one of several regions of the katG gene, the inhA regulatory and coding region, and the ahpC-oxyR, ndh,…”
BackgroundTuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm : Figure 1.
Chakraborty, S., & Rhee, K. Y. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a021147 · Cited by 144
“…a similar approach, Jacobs and colleagues isolated and genetically characterized mutants of M. smegmatis resistant to INH and ethionamide (a closely related analog) but exhibiting wild-type levels of catalase activity and susceptibility to other antitubercular compounds (Banerjee et al. 1994).”
BackgroundMdluli, K., Sherman, D. R., Hickey, M. J., Kreiswirth, B. N., Morris, S., Stover, C. K., & Barry, C. E. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.5.1085 · Cited by 112
“Recently, a genetic approach revealed a protein that, when hyperexpressed, conferred INH resistance on Mycobacterium smegmatis [12].”
InfluentialSilva, M. S. N., Senna, S. G., Ribeiro, M. O., Valim, A. R. D. M., Telles, M. A. S., Kritski, A. L., Morlock, G. P., Cooksey, R. C., Zaha, A., & Rossetti, M. L. R. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.9.4471-4474.2003 · Cited by 133
“Several studies have evaluated genes and genomic regions of Mycobacterium tuberculosis involved in the development of resistance to isoniazid (INH), such as katG, encoding catalaseperoxidase, which transforms INH into its active form, inhA, encoding a putative mycolic acid synthesis enzyme involved in cell wall format…”
BackgroundResultMarcinkeviciene, J. A., Magliozzo, R. S., & Blanchard, J. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22290 · Cited by 112
Azad, A. K., Sirakova, T. D., Rogers, L. M., & Kolattukudy, P. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4787 · Cited by 111
Alland, D., Kramnik, I., Weisbrod, T. R., Otsubo, L., Cerny, R., Miller, L. P., Jacobs, W. R., & Bloom, B. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.22.13227 · Cited by 130
Self-citationIsoniazid-Induced Transient High-Level Resistance in Mycobacterium tuberculosis
Viveiros, M., Portugal, I., Bettencourt, R., Victor, T. C., Jordaan, A. M., Leandro, C., Ordway, D. J., & Amaral, L. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.2804-2810.2002 · Cited by 110
“tuberculosis to INH takes place is very complex and has been ascribed to the individual mutation of genes encoding a catalase-peroxidase (katG) (30, 32), an enzyme of the mycolic acid pathway (inhA) (1), and a -ketoacyl-acyl carrier protein synthetase (kasA) (12).”
BackgroundKelley, C. L., Rouse, D. A., & Morris, S. L. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.9.2057 · Cited by 110
Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis
Karakousis, P. C., Williams, E. P., & Bishai, W. R. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm485 · Cited by 118
Codon usage in the Mycobacterium tuberculosis complex
Andersson, S. G. E., & Sharp, P. M. (1996) · Microbiology · doi:10.1099/00221287-142-4-915 · Cited by 109
Drobniewski, F. A., Cooke, M., Jordan, J., Casali, N., Mugwagwa, T., Broda, A., Townsend, C. L., Sivaramakrishnan, A., Green, N., Jit, M., et al. (2015) · Health Technology Assessment · doi:10.3310/hta19340 · Cited by 121
Safety and Tolerability Profile of Second-Line Anti-Tuberculosis Medications
Ramachandran, G., & Swaminathan, S. (2015) · Drug Safety · doi:10.1007/s40264-015-0267-y · Cited by 111
Drobniewski, F. A., & Wilson, S. M. (1998) · Journal of Medical Microbiology · doi:10.1099/00222615-47-3-189 · Cited by 123
Kurz, S. G., Furin, J. J., & Bark, C. M. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.010 · Cited by 126
“Alternatively, increased expression of inhA caused by alterations in the promoter region is associated with low level INH resistance as well as cross resistance to ethionamide [14, 15].”
BackgroundStructure of Acyl Carrier Protein Bound to FabI, the FASII Enoyl Reductase from Escherichia coli
Rafi, S., Novichenok, P., Kolappan, S., Zhang, X., Stratton, C. F., Rawat, R., Kisker, C., Simmerling, C. L., & Tonge, P. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608758200 · Cited by 120
Dover, L. G., Corsino, P. E., Daniels, I. R., Cocklin, S., Tatituri, V., Besra, G. S., & Fütterer, K. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.003 · Cited by 111
Costa, E. R. D., Ribeiro, M. O., Silva, M. S., Arnold, L. S., Rostirolla, D. C., Cafrune, P. I., Calderon, R. I., Palaci, M., Telles, M. A. S., Ritacco, V., et al. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-39 · Cited by 107
“tuberculosis drug resistance has been proposed to guide appropriate treatment policies [4].”
Wengenack, N. L., Uhl, J. R., Amand, A. L. S., Tomlinson, A. J., Benson, L. M., Naylor, S., Kline, B. C., Cockerill, F. R., & Rusnak, F. M. (1997) · The Journal of Infectious Diseases · doi:10.1086/514096 · Cited by 108
“matic components required for the synthesis of mycolic acids, which are necessary constituents of the mycobacterial cell wall [4, 5].”
BackgroundPuech, V., Bayan, N., Salim, K., Leblon, G., & Daffé, M. (2000) · Molecular Microbiology · doi:10.1046/j.1365-2958.2000.01738.x · Cited by 106
“These compounds are thought to play a central role in the physiology of the bacteria because their synthesis is one of the targets of the antituberculosis drugs isoniazid and ethionamide (Banerjee et al., 1994) and they participate in the cell wall permeability barrier (Brennan and Nikaido, 1995; Draper, 1998).”
BackgroundSusceptibility of Mycobacterium bovis BCG Vaccine Strains to Antituberculous Antibiotics
Ritz, N., Tebruegge, M., Connell, T. G., Sievers, A. S., Robins-Browne, R. M., & Curtis, N. C. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01302-08 · Cited by 106
“Subsequently, the gene inhA, whose mutation or overexpression leads to resistance against isoniazid and ethionamide, was identified in Mycobacterium smegmatis (2).”
BackgroundTargeting the Formation of the Cell Wall Core of M. tuberculosis
Barry, C. E., Crick, D. C., & McNeil, M. R. (2007) · Infectious Disorders - Drug Targets · doi:10.2174/187152607781001808 · Cited by 106
Amycomicin is a potent and specific antibiotic discovered with a targeted interaction screen
Pishchany, G., Mevers, E. E., Ndousse-Fetter, S., Horvath, D. J., Paludo, C. R., da Silva-Junior, E. A., Koren, S., Skaar, E. P., Clardy, J., & Kolter, R. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807613115 · Cited by 110
Shirude, P. S., Madhavapeddi, P., Naik, M., Murugan, K., Shinde, V. N., Nandishaiah, R., Bhat, J., Kumar, A., Hameed, S., Holdgate, G. A., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4012033 · Cited by 108
Wilson, T., de Lisle, G. W., Marcinkeviciene, J. A., Blanchardand, J. S., & Collins, D. M. (1998) · Microbiology · doi:10.1099/00221287-144-10-2687 · Cited by 107
“Mutations which appear to confer lowlevel INH resistance have been identified in the coding sequence of inhA (Banerjee et al., 1994; Kapur et al., 1995), and more commonly in the inhA promoter (Musser et al.”
BackgroundSelf-citationThe Mycobacterium tuberculosis Drugome and Its Polypharmacological Implications
Kinnings, S., Xie, L., Fung, K. H., Jackson, R. M., Xie, L., & Bourne, P. E. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000976 · Cited by 109
“tubercular agent isoniazid [30].”
Mycobacterial Cell Wall: A Source of Successful Targets for Old and New Drugs
Vilchèze, C. (2020) · Applied Sciences · doi:10.3390/app10072278 · Cited by 126
“In M. smegmatis and M. bovis BCG, mutants co-resistant to INH and ETH were isolated carrying mutations in ndh, a gene encoding an NADH dehydrogenase whose function is to oxidize NADH into NAD+.”
BackgroundInfluentialRNA signatures allow rapid identification of pathogens and antibiotic susceptibilities
Barczak, A. K., Gomez, J. E., Kaufmann-Malaga, B., Hinson, E. R., Cosimi, L. A., Borowsky, M. L., Onderdonk, A. B., Stanley, S. A., Kaur, D., Bryant, K. F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119540109 · Cited by 105
“The first resistant strain has a mutation in katG, which encodes a catalase necessary for prodrug activation (28); the second has a mutation in the promoter of inhA, which encodes the target of isoniazid (29).”
BackgroundMenendez, C., Gau, S., Lherbet, C., Rodriguez, F., Inard, C., Pasca, M. R., & Baltas, M. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.09.013 · Cited by 105
Zahrt, T. C., & Deretic, V. P. (2002) · Antioxidants and Redox Signaling · doi:10.1089/152308602753625924 · Cited by 118
Qiu, X., Choudhry, A. E., Janson, C. A., Grooms, M. H., Daines, R. A., Lonsdale, J. T., & Khandekar, S. S. (2005) · Protein Science · doi:10.1110/ps.051501605 · Cited by 106
“For example, triclosan inhibits bacterial FabI (McMurry et al. 1998; Qiu et al. 1999b); the antituberculosis drug isoniazid inhibits enoyl-ACP reductase and potentially other components of mycolic acid synthesis (Banerjee et al. 1994; Mdluli et al. 1998; Slayden et al. 2000).”
BackgroundCohen‐Gonsaud, M., Ducasse-Cabanot, S., Hoh, F., Zerbib, D., Labesse, G., & Quémard, A. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00463-1 · Cited by 101
“The inhA gene is assumed to form an operon together with the upstream ORF, mabA ( fabG1; Rv1483; SWISSPROT: Q48930).(11) MabA has been shown recently to be part of the FAS-II system and to catalyse the second step of an elongation round, i.”
BackgroundSusceptibility Test Methods: Mycobacteria, Nocardia , and Other Actinomycetes
Woods, G. L., Lin, S.-Y. G., & Desmond, E. P. (2011) · Wiley eBooks · doi:10.1128/9781555816728.ch73 · Cited by 111
Molecular Genetics of Mycobacteriophages
Hatfull, G. F. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0032-2013 · Cited by 120
Laval, T., Chaumont, L., & Demangel, C. (2021) · Immunological Reviews · doi:10.1111/imr.12952 · Cited by 118
Drug sensitivity and environmental adaptation of myocobacterial cell wall components
Barry, C. E., & Mdluli, K. E. (1996) · Trends in Microbiology · doi:10.1016/0966-842x(96)10031-7 · Cited by 102
Khandekar, S. S., Gentry, D. R., Aller, G. S. V., Warren, P. V., Xiang, H., Silverman, C., Doyle, M. L., Chambers, P. A., Konstantinidis, A. K., Brandt, M. A., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101769200 · Cited by 100
Riska, P. F., Su, Y., Bardarov, S. S., Freundlich, L. F., Sarkis, G. J., Hatfull, G. F., Carrière, C., Kumar, V., Chan, J., & Jacobs, W. R. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.4.1144-1149.1999 · Cited by 116
“smegmatis—mc(2)17 (rifampin resistant) (unpublished), mc(2)651 (isoniazid [INH]-resistant) (3), and mc(2)1255 (streptomycin resistant) (25)—are from our reference collection.”
Self-citationIsoniazid-resistant tuberculosis: a cause for concern?
Stagg, H. R., Lipman, M. C. I., McHugh, T. D., & Jenkins, H. E. (2017) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.16.0716 · Cited by 99
Cardoso, R. F., Cooksey, R. C., Morlock, G. P., Barco, P., Cecon, L., Forestiero, F., Leite, C. Q. F., Sato, D. N., Shikama, M. D. L. M., Mamizuka, E. M., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.9.3373-3381.2004 · Cited by 102
“The overexpression of InhA because of an upregulation mutation in the promoter region of inhA (preceding the mabA-inhA operon) can also cause resistance to INH by a titration mechanism (1, 2, 3, 8, 16, 23).”
BackgroundIdentification of KasA as the cellular target of an anti-tubercular scaffold
Abrahams, K. A., Chung, C., Ghidelli, S., Rullás, J., Rebollo-López, M. J., Gurcha, S. S., Cox, J. A. G., Mendoza-Losana, A., Jiménez‐Navarro, E., Martínez, M. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12581 · Cited by 99
Stanley, S. A., Kawate, T., Iwase, N., Shimizu, M., Clatworthy, A. E., Kazyanskaya, E., Sacchettini, J. C., Ioerger, T. R., Siddiqi, N. A., Minami, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302114110 · Cited by 94
“Isoniazid (INH), a central component of the more effective antituberculosis treatment regimens, similarly targets mycolic acid biosynthesis through inhibition of InhA (11).”
BackgroundInfluentialTargeting the mycobacterial envelope for tuberculosis drug development
Favrot, L., & Ronning, D. R. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.91 · Cited by 112
Mycolic acids: deciphering and targeting the Achilles' heel of the tubercle bacillus
Nataraj, V., Varela, C., Javid, A., Singh, A., Besra, G. S., & Bhatt, A. (2015) · Molecular Microbiology · doi:10.1111/mmi.13101 · Cited by 95
“Indeed, the hallmark anti-TB drug targets InhA, the core FAS-II component (Banerjee et al., 1994).”
BackgroundCrystallographic analysis of triclosan bound to enoyl reductase
Roujeinikova, A., Levy, C., Rowsell, S., Sedelnikova, S. E., Baker, P. J., Minshull, C. A., Mistry, A., Colls, J. G., Camble, R., Stuitje, A. R., et al. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3240 · Cited by 93
“However, as with other antibiotics, bacterial strains resistant to each of these compounds have been identi®ed (Furia & Schenkel, 1968; Turnowsky et al., 1989; Kater et al., 1994; Banerjee et al., 1994).”
BackgroundVeyron‐Churlet, R., Guerrini, O., Mourey, L., Daffé, M., & Zerbib, D. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04334.x · Cited by 91
The nonredundant roles of two 4′-phosphopantetheinyl transferases in vital processes of Mycobacteria
Chalut, C., Botella, L., d’Auria, C. D. S., Houssin, C., & Guilhot, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511129103 · Cited by 92
Pham, T. T., Jacobs-Sera, D., Pedulla, M. L., Hendrix, R. W., & Hatfull, G. F. (2007) · Microbiology · doi:10.1099/mic.0.2007/008904-0 · Cited by 95
Brossier, F., Véziris, N., Truffot-Pernot, C., Jarlier, V., & Sougakoff, W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01030-10 · Cited by 98
“Y386C (TAC 3 TGC) wt wt wt ND ND ND S315T HL (1) Y461H (TAC 3 CAC) wt wt wt ND ND ND S315T HL (1) Q269AMB (CAG 3 TAG) wt 15C 3 T wt ND ND ND A110V LL (6), HL (1) G124D (GGC 3 GAC) wt 15C 3 T, 102G 3 A wt ND ND ND wt HL (1) TC insertion after 675 wt 15C 3 T wt ND ND ND S315T HL (1) A insertion after 1391 wt 15C 3 T wt…”
BackgroundInfluentialDrug resistance mechanisms and novel drug targets for tuberculosis therapy
Islam, M. M., Hameed, H. M. A., Mugweru, J., Chhotaray, C., Wang, C., Tan, Y., Liu, J., Li, X., Tan, S., Ojima, I., et al. (2016) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2016.10.002 · Cited by 102
Carel, C., Nukdee, K., Cantaloube, S., Bonne, M., Diagne, C. T., Laval, F., Daffé, M., & Zerbib, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097148 · Cited by 89
“overproduction induces an increase in the level of INH resistance by trapping the INH-NAD adducts in its catalytic pocket, thus reducing INH concentration within the bacteria [43].”
BackgroundIdentification of the apparent carrier in mycolic acid synthesis.
Besra, G. S., Sievert, T., Lee, R. E., Slayden, R. A., Brennan, P. J., & Takayama, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.26.12735 · Cited by 90
Hiltunen, J. K., Chen, Z., Haapalainen, A. M., Wierenga, R. K., & Kastaniotis, A. J. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2009.08.001 · Cited by 94
Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis
Zhang, M., Sala, C., Hartkoorn, R. C., Dhar, N., Mendoza-Losana, A., & Cole, S. T. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01125-12 · Cited by 99
“The series included five inhibitors of mycolic acid synthesis or translocation, namely, INH, ETH, TLM, SQ109, and isoxyl (3, 24, 29, 38, 41, 42); three compounds targeting the arabinogalactan layer, PBTZ169, KRT2029, and EMB (5, 24); and three inhibitors of peptidoglycan synthesis, MER, AMOX (with and without CLAV), a…”
MethodThe Molecular Genetics of Mycolic Acid Biosynthesis
Pawełczyk, J., & Kremer, L. (2014) · Microbiology Spectrum · doi:10.1128/microbiolspec.mgm2-0003-2013 · Cited by 103
“tuberculosis (83), and the InhA protein was demonstrated to catalyze the 2trans-enoyl-ACP reduction, with a preference for longchain substrates (82) (Fig.”
BackgroundBrown, A. K., Papaemmanouil, A., Bhowruth, V., Bhatt, A., Dover, L. G., & Besra, G. S. (2007) · Microbiology · doi:10.1099/mic.0.2007/009936-0 · Cited by 101
“tuberculosis FAS-II has proven as a clinically relevant target (Banerjee et al., 1994; Dover et al., 2007; Kremer et al., 2000).”
BackgroundSynthesis and Evaluation of Nitrofuranylamides as Novel Antituberculosis Agents
Tangallapally, R. P., Yendapally, R., Lee, R. E., Hevener, K. E., Jones, V., Lenaerts, A. J. M., McNeil, M., Wang, Y., Franzblau, S. G., & Lee, R. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049972y · Cited by 90
Wei, C., Lei, B., Musser, J. M., & Tu, S. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.670-675.2003 · Cited by 89
“ductase (InhA) (1) and the -ketoacyl acyl carrier protein”
BackgroundQuémard, A., Dessen, A., Sugantino, M., Jacobs, W. R., Sacchettini, J. C., & Blanchard, J. S. (1996) · Journal of the American Chemical Society · doi:10.1021/ja950998b · Cited by 90
Self-citationAntibiotic resistance in the absence of selective pressure
Gillespie, S. H. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00340-x · Cited by 94
“Since then, the molecular mechanism of resistance has been described for all of the main anti-tuberculosis drugs including isoniazid [10–13], pyrazinamide [14], streptomycin [15], ethambutol [16] and fluoroquinolones [17].”
BackgroundPlatensimycin, a New Antibiotic and “Superbug Challenger” from Nature
Häbich, D., & von Nussbaum, F. (2006) · ChemMedChem · doi:10.1002/cmdc.200600145 · Cited by 89
Timmins, G. S., Master, S. S., Rusnak, F. M., & Deretic, V. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3006-3009.2004 · Cited by 90
“Several INH-derived intermediates generated during INH activation, such as isonicotinic acyl NADH (20) and mycobacterial targets including enzymes from the mycobacterial type II fatty acid synthase system (1, 16), have”
BackgroundResultUpton, A. M., Mushtaq, A., Victor, T. C., Sampson, S. L., Sandy, J., Smith, D., van Helden, P. D., & Sim, E. (2001) · Molecular Microbiology · doi:10.1046/j.1365-2958.2001.02648.x · Cited by 96
“This disruption occurs via the inhibition of the type II fatty acid synthase, FASII, required for full-length extension of the meromycolate chain (Banerjee et al., 1994; Mdluli et al., 1998; Rozwarski et al., 1998).”
BackgroundFeuerriegel, S., Oberhauser, B., George, A., Dafae, F. M., Richter, E., Rüsch–Gerdes, S., & Niemann, S. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-90 · Cited by 89
Engström, A., Morcillo, N., Imperiale, B. R., Hoffner, S. E., & Juréen, P. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06664-11 · Cited by 92
“Mutations in the open reading frame of inhA confer INH resistance (3); however, these mutations are rarely found in clinical isolates and usually occur together with mutations in katG and the promoter region of inhA (60).”
BackgroundWendler, F., Bergler, H., Prutej, K., Jungwirth, H., Zisser, G., Kuchler, K., & Högenauer, G. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27091 · Cited by 87
Phage therapy as a renewed therapeutic approach to mycobacterial infections: a comprehensive review
Azimi, T., Mosadegh, M., Nasiri, M. J., Sabour, S., Karimaei, S., & Nasser, A. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s218638 · Cited by 87
“41 Moreover, SWU1gp39 increases the susceptibility of Mtb to various stresses including heat shock, H2O2, SDS, and low PH. 41,93 On the other hand, a putative GTPase-activating protein (GAP) is encoded with mycobacteriophage SWU1 A321_gp67.”
Nguyen, M., Quémard, A., Broussy, S., Bernadou, J., & Meunier, B. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2137-2144.2002 · Cited by 86
“Studies (22, 23, 26) have suggested that the activated form of INH, probably an isonicotinoyl radical, is capable of reacting with the -NAD (NAD /NADH) which is the cofactor of the long-chain 2-trans-enoyl-acyl carrier protein reductase InhA (2, 20).”
BackgroundAn Expedient Asymmetric Synthesis of Platencin
Nicolaou, K. C., Toh, Q. Y., & Chen, D. Y. ‐. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804588r · Cited by 82
The Expanding Diversity of Mycobacterium tuberculosis Drug Targets
Wellington, S., & Hung, D. T. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00255 · Cited by 87
In vivo veritas: The search for TB drug targets goes live
McKinney, J. D. (2000) · Nature Medicine · doi:10.1038/82142 · Cited by 96
Responses of Mycobacterium tuberculosis to Growth in the Mouse Lung
Dubnau, E., Chan, J., Mohan, V. P., & Smith, I. (2005) · Infection and Immunity · doi:10.1128/iai.73.6.3754-3757.2005 · Cited by 83
“tuberculosis, based upon overexpression of inhA, coding for an enoyl-ACP-reductase, a protein required for mycolic acid biosynthesis and the major target of isoniazid (INH) (1).”
BackgroundMethodSelf-citationTaniguchi, H., Chang, B., Abe, C., Nikaido, Y., Mizuguchi, Y., & Yoshida, S. I. (1997) · Journal of Bacteriology · doi:10.1128/jb.179.15.4795-4801.1997 · Cited by 91
“It is also known that resistance to isoniazid is due to changes in the catalase-peroxidase gene (katG) (8) or the inhA gene (2).”
BackgroundA review of the use of ethionamide and prothionamide in childhood tuberculosis
Thee, S. A., Garcia‐Prats, A. J., Donald, P. R., Hesseling, A. C., & Schaaf, H. S. (2015) · Tuberculosis · doi:10.1016/j.tube.2015.09.007 · Cited by 82
Novel targets in M. tuberculosis: search for new drugs
Lamichhane, G. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.10.004 · Cited by 96
Proteome-wide Profiling of Isoniazid Targets in Mycobacterium tuberculosis
Argyrou, A., Jin, L., Siconolfi-Baez, L., Angeletti, R. H., & Blanchard, J. S. (2006) · Biochemistry · doi:10.1021/bi061874m · Cited by 81
“INH and ethionamide, a structural analog of INH, were both shown to have a point mutation (S94A) in the inhA-encoded enoyl-ACP reductase (5).”
BackgroundKremer, L., Dover, L. G., Morbidoni, H. R., Vilchèze, C., Maughan, W. N., Baulard, A. R., Tu, S., Honoré, N., Deretic, V. P., Sacchettini, J. C., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302435200 · Cited by 96
Metadata
- Authors
- Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R.
- Affiliations
- Albert Einstein College of Medicine (US)
- Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, NY 10461.
- AgResearch (NZ)
- AgResearch, Wallaceville Animal Research Center, Upper Hutt, New Zealand.
- Venue
- Science
- Published
- 1994-01-14
- Volume
- 263
- Issue
- 5144
- Pages
- 227-230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2075000963
- Cited by
- 1,389
- References
- 46
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 31 · 2023: 43 · 2022: 49 · 2021: 39 · 2020: 45 · 2019: 52 · 2018: 52 · 2017: 62 · 2016: 45 · 2015: 54 · 2014: 69 · 2013: 39 · 2012: 57
- FWCI
- 46.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u01ai030189-03)
- National Institute of Allergy and Infectious Diseases (AI 27160, UO1AI30189)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Keywords
- inhA gene, isoniazid, ethionamide, Mycobacterium tuberculosis, therapeutic target, drug resistance, missense mutations, mycolic acid biosynthesis, Mycobacterium smegmatis, Mycobacterium bovis BCG, antitubercular agents
- MeSH terms
- Amino Acid Sequence, Bacterial Proteins, Base Sequence, Cloning, Molecular, Drug Resistance, Microbial, Ethionamide, Genes, Bacterial, Isoniazid, Molecular Sequence Data, Mutation, Mycobacterium, Mycobacterium bovis, Mycobacterium tuberculosis, Mycolic Acids, Oxidoreductases, Open Reading Frames, Sequence Alignment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.